Lisdexamfetamine (Vyvanse): the legal and safety record

The 2014 settlement: civil allegations, resolved without a plea

On 24 September 2014, Shire Pharmaceuticals LLC agreed to pay $56.5 million — $35.7 million to the federal government, $20.8 million to state Medicaid programs — to resolve what the Department of Justice described as civil allegations that it violated the False Claims Act in marketing five drugs, including Vyvanse [1]. The Vyvanse allegations, laid out in the settlement agreement itself, cover February 2007 through September 2010: certain sales representatives allegedly promoted the drug as “non-abuseable” or less abuseable than Adderall XR “despite a lack of clinical data sufficient to support such a claim”; one medical science liaison allegedly told a state formulary board that Vyvanse “provides less abuse liability” than “every other long-acting release mechanism” on the market; and the company allegedly made unsupported claims that treatment would prevent car accidents, divorce, being arrested, and unemployment [1][2]. Representatives also allegedly made improper calls to state Medicaid programs to push prescriptions through prior authorization, without disclosing they worked for Shire [2].

Now the other direction, stated with equal precision. This was a civil settlement: no criminal charge, no guilty plea. DOJ’s own release ends, “The claims resolved by the settlement are allegations only; there has been no determination of liability” [1] — and the agreement adds that it is “neither an admission of liability by Shire nor a concession by the United States or Relators that their claims are not well founded,” and that Shire expressly denies the allegations [2]. The matter came to the government the way most False Claims Act cases do: whistleblower suits — one by Dr. Gerardo Torres, a former Shire executive, who received $5.9 million of the recovery, and one by three former Shire sales representatives [1][2]. Shire also signed a corporate integrity agreement with HHS-OIG covering its future marketing [1].

The boxed warning the sales pitch contradicted

What makes the Vyvanse allegations specific rather than generic pharma-scandal material is that the alleged claim collided with the drug’s own label. The settlement documents note that during the alleged conduct, “as an amphetamine product, the Vyvanse label included an FDA-mandated black box warning for its potential for misuse and abuse” [1]. That warning is still there. The current label, revised 04/2026, opens [4]:

“WARNING: ABUSE, MISUSE, AND ADDICTION — VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.”

— VYVANSE prescribing information, boxed warning, revision 04/2026 [4]. (The boxed warning’s title has changed over the years; this is the current text, not the 2007–2010 wording.)

The label also states the scheduling fact plainly: “VYVANSE contains lisdexamfetamine, a prodrug of amphetamine, a Schedule II controlled substance” [4]. Schedule II means both halves at once — an accepted medical use, and the most restrictive federal controls short of banning it, because of high abuse potential. Neither half cancels the other, and a page that quotes only one of them is selling you something.

There is also a court-of-record footnote to the marketing story: on 6 May 2011, FDA’s drug-advertising division sent Shire a warning letter over a Vyvanse promotional magnet whose design let a sales representative’s business card cover most of the printed risk information — misbranding, in FDA’s words, because the piece suggested Vyvanse “is safer and more effective than has been demonstrated” [3]. FDA’s live site no longer hosts pre-2017 promotional-enforcement letters, so we cite the archived copy and say so rather than pretending the link is evergreen [3].

What the record does not decide

Hold both halves here too. The settled record is about marketing conduct — claims allegedly made beyond the data between 2007 and 2010, under a company that no longer exists as such (Takeda acquired Shire in 2019 and now holds the approval [4]). It is not a finding that Vyvanse harmed any particular patient, and it is not evidence that the drug does not work. Vyvanse has approval trials behind both of its indications — ADHD in 2007, and moderate to severe binge eating disorder in adults, approved 30 January 2015 by efficacy supplement [5], with the label’s own limitation that it “is not indicated or recommended for weight loss” [4]. Roughly 9.9 million US prescriptions and 1.6 million patients in 2024 [7] sit on top of that evidence base — the volume, the label, and the adverse-event reporting are on our lisdexamfetamine page, caveats first, and the ADHD approval trial sits in our trial-length page with everything else’s.

A schedule II stimulant page usually slides one of two ways: into drug-war moralizing, where the boxed warning becomes an argument against treating ADHD at all, or into marketing-copy neutrality, where a $56.5 million settlement becomes a footnote. The record supports neither. It supports exactly this: the government alleged the abuse-safety claims were overstated and Shire paid to resolve it without admitting it; the boxed warning is real and belongs in any honest description of the drug; and the decision to treat ADHD with a stimulant is a clinical question the approval evidence speaks to and this page does not.

What is not in the record

• No criminal charge or plea. The 2014 resolution was civil from start to finish. Any page that says Shire was “convicted” or “found guilty” over Vyvanse marketing is wrong on the record [1][2].
• No Class I recall (within openFDA’s ~2012-onward coverage window). Eleven recall records, ten Class II and one Class III — most of the ongoing ones are 2025–2026 generic-manufacturer dissolution failures, a quality problem with specific lots rather than anything about the molecule [6].
• No adjudicated injury verdicts. The settled matter was about marketing statements and payer losses — not a court finding that Vyvanse injured any patient. A page that lets you infer otherwise is overreaching, in either direction.

Common questions

What was the 2014 Shire settlement about?

On 24 September 2014, Shire Pharmaceuticals LLC agreed to pay $56.5 million to resolve civil allegations that it violated the False Claims Act through the marketing of Adderall XR, Vyvanse, Daytrana, Pentasa and Lialda. For Vyvanse, the government alleged that between February 2007 and September 2010 Shire representatives made false and misleading statements about the drug’s efficacy and abuse liability to state Medicaid formulary committees and individual physicians, and made unsupported claims that treatment would prevent car accidents, divorce, arrests and unemployment. It was a civil settlement: no criminal charge, no guilty plea, and DOJ’s release states that the claims are allegations only with no determination of liability.

Did Shire admit to anything?

No. The settlement agreement itself — hosted on justice.gov — says the agreement is made in compromise of disputed claims, is neither an admission of liability by Shire nor a concession by the United States that its claims are not well founded, and that Shire expressly denies the allegations. That is materially different from the Warner-Lambert matter on our gabapentin page, where a company pleaded guilty in criminal court. A page that presents the two as the same kind of event is being imprecise in the direction of prosecution; one that omits the allegations is being imprecise in the direction of marketing.

Does Vyvanse have a black box warning?

Yes. The current label (revised 04/2026) opens with “WARNING: ABUSE, MISUSE, AND ADDICTION”: Vyvanse has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction, and misuse and abuse of CNS stimulants can result in overdose and death. The boxed warning existed in the 2007–2010 period too — the government’s settlement documents point out that the label carried an FDA-mandated black box warning for abuse potential during the very years Shire representatives allegedly described the drug as less abusable than every competitor.

What does schedule II actually mean?

Lisdexamfetamine is a prodrug of amphetamine, which federal law places in schedule II — the most restrictive category for drugs that have an accepted medical use. Schedule II drugs are recognized as legitimate medicine and simultaneously classified as having a high potential for abuse; in practice it means tighter prescribing rules than most drugs, such as no refills on a single prescription. It is not a statement that any individual patient is abusing anything, and it is not a reason on its own to stop a medication that is working.

Has Vyvanse or generic lisdexamfetamine been seriously recalled?

No Class I recall — FDA’s most serious category — appears in the openFDA enforcement database (which is reliable only from roughly 2012 onward, so this is a statement about the covered window). Eleven records exist: ten Class II and one Class III. Eight were still listed as ongoing at verification, most of them 2025–2026 recalls of generic lisdexamfetamine capsules by Sun Pharmaceutical for failed dissolution specifications — a manufacturing-quality problem with specific generic lots, not a finding about the molecule.

Is any of this a reason to stop taking Vyvanse?

No. Nothing on this page is medical advice, and nothing in a twelve-year-old civil settlement about marketing conduct tells you whether the drug is working for you. Stimulant treatment for ADHD is supported by the approval evidence, and Vyvanse — unlike some drugs in this series — has approval trials behind both of its indications. What the record changes is the weight you give marketing-flavored claims about abuse-proofness: the label’s boxed warning, not the sales pitch, is the document to trust. If you have concerns about dependence or side effects, that is a conversation with your prescriber, not a reason to stop on your own.

Sources

Last verified 2026-09-08. Corrections change this date.